Pre-market hot trades in US stocks: Haverty Furniture-A pre-market down 20.71%; ZW Data Action Tech pre-market down 17.31%

Popular Pre-Market Trades in US Stocks Haverty Furniture-A is down 20.71% in pre-market trading. There are no significant recent news; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news ZW Data Action Tech is down 17.31% in pre-market trading, with no significant recent news. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Top Gainers in Pre-Market Trading in US Stocks RenX Enterprises is up 150.50% in pre-market trading. Based on recent key news: On February 10, RenX Enterprises' subsidiary Zimmer Equipment Inc. won a new transportation contract in Florida. This contract is expected to generate recurring revenue and improve fleet utilization, driving a significant increase in stock price. Source: Reuters On February 10, RenX Enterprises released relevant information via GlobeNewswire, emphasizing the importance of the contract and its potential benefits. Source: GlobeNewswire There are no other significant recent news. The transportation industry has performed strongly recently, with clear capital inflows. Quince Therapeutics is up 57.04% in pre-market trading. Based on recent key news: On February 10, Quince Therapeutics announced the hiring of LifeSci Capital as a financial advisor to help explore restructuring and strategic alternatives. This move may trigger market optimism regarding the company's future development, leading to a significant increase in stock price. Source: WSJ On February 10, Quince Therapeutics' stock price rose 91.08% in pre-market trading, despite a 6.54% drop the previous day. This significant volatility may be a reaction to the market's response to the company's strategic adjustments. Source: Benzinga On February 11, analysts expect Quince Therapeutics' earnings per share to improve, although it will still be a loss. This expectation may boost investor confidence, driving the stock price up. Source: Benzinga Pro The biotechnology industry faces challenges, with increased market volatility. MNTN is up 37.27% in pre-market trading. Based on recent news, On February 11, MNTN reported strong fourth-quarter and full-year financial results, showing a 36% year-over-year revenue increase, primarily due to the strong performance of its Performance TV platform. Active Performance TV customers increased by 63% year-over-year. The company expects full-year revenue in 2026 to be between $345 million and $355 million, with a growth rate of 22.9%. This news boosted market confidence, driving a significant increase in stock price On February 11, MNTN announced a fourth-quarter GAAP earnings per share of $0.43, exceeding expectations by $0.20, with revenue of $87.09 million, a year-on-year increase of 24.8%, surpassing expectations by $9.1 million. The strong financial performance further boosted investor confidence, driving the stock price up. On February 11, analysts gave MNTN an average rating of "Buy," with 9 analysts rating it as "Strong Buy" or "Buy," and 1 analyst rating it as "Hold." Wall Street's 12-month median target price for MNTN is $22.50, approximately 173.7% higher than the closing price of $8.22 on February 9. The positive evaluations from analysts and high target price expectations further propelled the stock price upward. The advertising and marketing industry performed strongly overall, while macroeconomic factors still require attention regarding the risks of CTV adoption